We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$22.8B
AUM Growth
+$1.74M
Cap. Flow
+$81.8M
Cap. Flow %
0.36%
Top 10 Hldgs %
82.65%
Holding
132
New
12
Increased
20
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$137M
2
PACB icon
Pacific Biosciences
PACB
+$66.5M
3
KOD icon
Kodiak Sciences
KOD
+$50.2M
4
BLUE
bluebird bio
BLUE
+$50.2M
5
TVTX icon
Travere Therapeutics
TVTX
+$34M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$144M
2
ADCT icon
ADC Therapeutics
ADCT
+$34.5M
3
AMRN
Amarin Corp
AMRN
+$22.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$20.4M
5
NVTA
Invitae Corporation
NVTA
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPT
51
DELISTED
Opthea Limited American Depositary Shares
OPT
$27.1M 0.12%
3,382,797
-29,265
-0.9% -$222K
BCAB icon
52
BioAtla
BCAB
$5.3M
$24.3M 0.11%
16,500
– –
KDNY
53
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$24.3M 0.11%
1,903,069
+822,676
+76% +$10.8M
NVAX icon
54
Novavax
NVAX
$1.47B
$22.5M 0.1%
108,756
-35,000
-24% -$7.71M
RETA
55
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$22.5M 0.1%
223,976
– –
BCEL
56
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$22M 0.1%
3,532,760
– –
DSGN icon
57
Design Therapeutics
DSGN
$938M
$21.1M 0.09%
1,436,636
– –
ACHL
58
DELISTED
Achilles Therapeutics
ACHL
$20.2M 0.09%
2,591,366
– –
CRNX icon
59
Crinetics Pharmaceuticals
CRNX
$8.99B
$19.4M 0.09%
920,656
– –
DICE
60
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$19.3M 0.08%
+588,235
New +$20M
CNTA
61
DELISTED
Centessa Pharmaceuticals
CNTA
$18.8M 0.08%
1,127,273
+727,273
+182% +$15.1M
AXSM icon
62
Axsome Therapeutics
AXSM
$10.9B
$17.8M 0.08%
539,057
– –
SRZN icon
63
Surrozen
SRZN
$282M
$17.7M 0.08%
+166,667
New +$23.5M
OTIC
64
DELISTED
Otonomy, Inc.
OTIC
$14.8M 0.06%
7,694,038
+471,564
+7% +$800K
CYT
65
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$14.3M 0.06%
812,640
– –
MIRM icon
66
Mirum Pharmaceuticals
MIRM
$5.87B
$12.9M 0.06%
647,313
– –
ALBO
67
DELISTED
Albireo Pharma Inc
ALBO
$12.9M 0.06%
412,466
– –
ALT icon
68
Altimmune
ALT
$605M
$12.1M 0.05%
1,072,038
– –
TCRX icon
69
TScan Therapeutics
TCRX
$52.8M
$11.9M 0.05%
+1,425,000
New +$13.2M
ANAB icon
70
AnaptysBio
ANAB
$1.71B
$11.6M 0.05%
427,179
– –
AUPH icon
71
Aurinia Pharmaceuticals
AUPH
$2.22B
$11.5M 0.05%
520,523
-599,439
-54% -$9.51M
XENE icon
72
Xenon Pharmaceuticals
XENE
$5.88B
$11.5M 0.05%
751,639
– –
TNGX icon
73
Tango Therapeutics
TNGX
$4.03B
$9.7M 0.04%
+750,000
New +$8.99M
MGNX icon
74
MacroGenics
MGNX
$261M
$9.27M 0.04%
442,579
+241,900
+121% +$5.83M
KRTX
75
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$8.56M 0.04%
69,966
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2021 Portfolio in Review

As of Q3 2021, Julian Baker held 132 positions worth $22.8B, up 0.01% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker's Q3 2021 filing shows 12 new, 20 increased, 6 reduced and 10 closed positions. Its largest new stake was Surrozen: 166,667 shares worth $17.7M. The largest sale was Apellis Pharmaceuticals, an estimated $144M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q3 2021 buy was Surrozen: 166,667 shares worth $17.7M.
  • Julian Baker added most to Ascendis Pharma A/S in Q3 2021, an estimated $137M increase.
  • Julian Baker's biggest Q3 2021 reduction was Amarin Corp, cutting an estimated $22.6M.
  • Julian Baker fully exited Apellis Pharmaceuticals in Q3 2021, selling an estimated $144M.
  • Julian Baker's ten largest holdings make up 83% of its $22.8B portfolio in Q3 2021.
  • Julian Baker opened 12 new positions and closed 10 in Q3 2021.
  • Julian Baker's portfolio value rose 0.01% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.